Hiroi Clinic: Low-Dose Immunotherapy and End-Stage Cancer Care
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Located in Osaka and Tokyo, Hiroi Clinic is led by Dr. Hiroi, a seasoned specialist who believes in "never giving up on any possibility." The clinic is highly regarded for its precision-driven approach to immune checkpoint inhibitors.
Therapeutic Strategy: The Power of Low-Dose Combination
Dr. Hiroi’s protocol focuses on balancing efficacy with quality of life (QOL):
- Combined PD-1 and CTLA-4 Inhibition: Strategically uses Opdivo (Nivolumab) and Yervoy (Ipilimumab) at optimized low doses to re-activate the body's T-cell response.
- Reduced Side Effects: By using lower doses, the clinic aims to prevent severe immune-related adverse events (irAEs) like pneumonitis, making nurturing care sustainable for late-stage patients.
- Holistic Support: The clinic provides continuous monitoring and adjustments based on the patient's immediate response and physiological state.
[Medical Supporter Guardian Statement] Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.